Unique ID issued by UMIN | UMIN000042425 |
---|---|
Receipt number | R000048140 |
Scientific Title | Quantifying the burden of disease and perceived health state in patients with Hereditary Angioedema in Japan: Patient-Reported Outcomes study |
Date of disclosure of the study information | 2020/11/16 |
Last modified on | 2024/09/12 07:00:13 |
Quantifying the burden of disease and perceived health state in patients with Hereditary Angioedema in Japan: Patient-Reported Outcomes study
HAE-PRO study
Quantifying the burden of disease and perceived health state in patients with Hereditary Angioedema in Japan: Patient-Reported Outcomes study
HAE-PRO study
Japan |
Hereditary Angioedema
Clinical immunology | Dermatology | Adult |
Child |
Others
NO
To assess the health-related quality of life of Japanese patients with HAE using AE-QOL
Others
QOL
Exploratory
Others
Not applicable
To assess the health-related quality of life of Japanese patients with HAE using AE-QOL
1) To assess disease activity and mental health using AAS and HADS
2) To assess general health status and work productivity using SF-12 and WPAI
Observational
18 | years-old | <= |
75 | years-old | >= |
Male and Female
The subject has been diagnosed with HAE by a physician and is 18 years or older in age
Currently participating or planning to participate in any clinical trials and receiving any investigational agents for HAE treatment.
50
1st name | (1) Michihiro, (2) Yoichi |
Middle name | |
Last name | (1) Hide, (2) Inoue |
(1) Graduate School of Biomedical and Health Sciences, Hiroshima University
(2)Takeda Pharmaceutical Company Limited
(1) Department of Dermatology, (2)Japan Medical Office
(1)734-8551(2)103-8668
(1) 1-2-3, Minami-ku hiroshima-shi, (2)1-1, Nihonbashi-Honcho 2-chome, Chuo-ku,
(1)082-257-5235(2)070-4921-7478
yoichi.inoue@takeda.com
1st name | Miwa |
Middle name | |
Last name | Kishimoto |
Takeda Pharmaceutical Company Limited
Japan Medical Office
103-8668
1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, Japan
080-2171-9043
miwa.kishimoto@takeda.com
Takeda Pharmaceutical Company Limited
None
Self funding
Japan
None
None
Non-Profit Organization MINS Institutional Review Board
ST Shibuya Building 2F, 1-15-14 Dogenzaka, Shibuya-ku, Tokyo
03-6416-1868
npo-mins@j-irb.com
NO
なし
2020 | Year | 11 | Month | 16 | Day |
NA
Published
https://pubmed.ncbi.nlm.nih.gov/39258885/
54
All PROMs showed a substantial HRQoL impairment. Overall, the higher the attack frequencies, the greater the impairment in the PROMs tended to be reported. In multiple linear regression analyses, higher AE-QoL Fatigue/Mood and Fears/Shame domain scores were associated with higher HADS anxiety subscale scores; higher AE-QoL total scores and lower SF-12 Physical and Mental Health Composite scores were associated with higher HADS depression subscale scores.
2024 | Year | 09 | Month | 12 | Day |
NA
2024 | Year | 09 | Month | 11 | Day |
Male:7, Female: 47
HAE type I and II: 44
HAE type III: 5
Unknown: 5
Study participants were recruited from February 2021 to June 2021 through two HAE patient advocacy groups in Japan: Hereditary Angioedema Japan (HAEJ),43 a registered non-profit patient organization, and Kumi-mu.
NA
Patient reported outcomes using SF-12, AE-QoL, HADS, WPAI and PROM
NA
NA
Completed
2020 | Year | 09 | Month | 30 | Day |
2020 | Year | 10 | Month | 15 | Day |
2021 | Year | 02 | Month | 24 | Day |
2021 | Year | 06 | Month | 30 | Day |
None
2020 | Year | 11 | Month | 12 | Day |
2024 | Year | 09 | Month | 12 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048140